Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.50 |
| ▸ | MGLL | Q99685 | 3/20 | 0.49 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.46 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.45 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.42 |
| ▸ | GHSR | Q92847 | 1/20 | 0.42 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12099637 | 0.88 | HSD11B1 (0.40) | HSD11B1MGLLSCN9AMAPK7HRH3 | |
| SCHEMBL12188757 | 0.87 | HRH3 (0.48) | MGLLHRH3KMT2AMEN1 | |
| SCHEMBL1806136 | 0.81 | HRH3 (0.49) | MGLLHRH3KMT2A | |
| SCHEMBL1810576 | 0.79 | HSD11B1 (0.46) | HSD11B1MGLLSCN9AMAPK7HRH3 | |
| SCHEMBL1809573 | 0.79 | HSD11B1 (0.53) | HSD11B1MGLLSCN9AMAPK7HRH3 | |
| SCHEMBL1808768 | 0.78 | HSD11B1 (0.56) | HSD11B1MGLLKMT2AMEN1CACNA1B | |
| SCHEMBL1806858 | 0.78 | HSD11B1 (0.52) | HSD11B1MGLLSCN9AMAPK7PRKAA2 | |
| SCHEMBL1806739 | 0.78 | HSD11B1 (0.53) | HSD11B1MGLLSCN9AMAPK7PRKAA2 | |
| SCHEMBL1810939 | 0.78 | HSD11B1 (0.52) | HSD11B1MGLLSCN9AMAPK7KMT2A | |
| SCHEMBL1808027 | 0.78 | HSD11B1 (0.45) | HSD11B1MGLLSCN9AMAPK7PRKAA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9051296-B2 | Aryl carboxamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-06-09 | — | — | US | claimed |
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-09-13 | — | — | US | claimed |
| WO-2011058766-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2011-05-19 | — | — | WO | claimed |
| US-9051296-B2 | Aryl carboxamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-06-09 | — | — | US | disclosed |
| US-9051296-B2 | Aryl carboxamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-06-09 | — | — | US | disclosed |
| US-9051296-B2 | Aryl carboxamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-06-09 | — | — | US | disclosed |
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-09-13 | — | — | US | disclosed |
| WO-2011058766-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2011-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | SCN1B, SCN1A, SCN2B | HSD11B1 2985/4885MGLL 4513/4885SCN9A 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.